zoe
Lv46
560 积分
2022-02-16 加入
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2天前
已完结
-
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
4天前
已完结
-
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
7天前
已完结
-
Epidemiology, risk factors, and prognostic factors of gliomas
16天前
已完结
-
Structure and assembly of the human IL-12 signaling complex
25天前
已关闭
-
The breast cancer drug market
30天前
已关闭
-
What influences the activity of Degrader−Antibody conjugates (DACs)
1个月前
已完结
-
Degrader–Antibody Conjugates: Emerging New Modality
1个月前
已完结
-
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
2个月前
已完结
-
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
2个月前
已完结